Romanya -
Romence -
ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)
kardatuxan 2,5 mg
gedeon richter polska sp. z o.o. - polonia - rivaroxabanum - compr. film. - 2,5mg - antitrombotice inhibitori directi ai factorului xa
Romanya -
Romence -
ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)
kardatuxan 20 mg
gedeon richter polska sp. z o.o. - polonia - rivaroxabanum - compr. film. - 20mg - antitrombotice inhibitori directi ai factorului xa
Romanya -
Romence -
ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)
rivaroxaban stada 10 mg
stada arzneimittel ag - germania - rivaroxabanum - compr. film. - 10mg - antitrombotice inhibitori directi ai factorului xa
Romanya -
Romence -
ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)
rivaroxaban stada 15 mg
stada arzneimittel ag - germania - rivaroxabanum - compr. film. - 15mg - antitrombotice inhibitori directi ai factorului xa
Romanya -
Romence -
ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)
rivaroxaban stada 2,5 mg
stada arzneimittel ag - germania - rivaroxabanum - compr. film. - 2,5mg - antitrombotice inhibitori directi ai factorului xa
Romanya -
Romence -
ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)
rivaroxaban stada 20 mg
stada arzneimittel ag - germania - rivaroxabanum - compr. film. - 20mg - antitrombotice inhibitori directi ai factorului xa
Avrupa Birliği -
Romence -
EMA (European Medicines Agency)
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - alți agenți antineoplazici - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
Avrupa Birliği -
Romence -
EMA (European Medicines Agency)
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantle-cell - agenți antineoplazici - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
Avrupa Birliği -
Romence -
EMA (European Medicines Agency)
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - agenți antineoplazici - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.